Alaunos Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $-96.8M | $70.9M |
| FY2018 | — | $85.6M | $61.7M |
| FY2019 | — | $95.0M | $79.7M |
| FY2020 | $0 | $124.0M | $115.1M |
| FY2021 | $16.3M | $58.1M | $76.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2017 | — | $-96.8M | $70.9M |
| FY2018 | — | $85.6M | $61.7M |
| FY2019 | — | $95.0M | $79.7M |
| FY2020 | $0 | $124.0M | $115.1M |
| FY2021 | $16.3M | $58.1M | $76.1M |